Cell therapy in Sjögren's syndrome: opportunities and challenges

被引:0
作者
Lu, Yangyang [1 ,2 ,3 ]
Shi, Rongjing [1 ,2 ,3 ]
He, Wenqin [1 ,2 ,3 ]
An, Qi [1 ,2 ,3 ]
Zhao, Jingwen [1 ,2 ,3 ]
Gao, Xinnan [1 ,2 ,3 ]
Zhang, Baiyan [1 ,2 ,3 ]
Zhang, Liyun [1 ,2 ,3 ]
Xu, Ke [1 ,2 ,3 ]
Ma, Dan [1 ,2 ,3 ,4 ]
机构
[1] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Hosp 3, Taiyuan, Peoples R China
[2] Shanxi Prov Clin Res Ctr Dermatol & Immunol Dis Rh, Taiyuan, Peoples R China
[3] Shanxi Prov Clin Theranost Technol Innovat Ctr Imm, Taiyuan, Peoples R China
[4] Shanxi Acad Adv Res & Innovat, Taiyuan, Peoples R China
来源
EXPERT REVIEWS IN MOLECULAR MEDICINE | 2024年 / 26卷
基金
中国博士后科学基金;
关键词
CAT-T; cell therapy; extracellular vesicles; HSCs; iPSCs; MSCs; Sj & ouml; gren's syndrome; MESENCHYMAL STEM-CELLS; SJOGRENS-SYNDROME; EXTRACELLULAR VESICLES; TRANSPLANTATION;
D O I
10.1017/erm.2024.21
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sj & ouml;gren's syndrome (SS) is a chronic autoimmune disease caused by immune system disorders. The main clinical manifestations of SS are dry mouth and eyes caused by the destruction of exocrine glands, such as the salivary and lacrimal glands, and systemic manifestations, such as interstitial pneumonia, interstitial nephritis and vasculitis. The pathogenesis of this condition is complex. However, this has not been fully elucidated. Treatment mainly consists of glucocorticoids, disease-modifying antirheumatic drugs and biological agents, which can only control inflammation but not repair the tissue. Therefore, identifying methods to regulate immune disorders and repair damaged tissues is imperative. Cell therapy involves the transplantation of autologous or allogeneic normal or bioengineered cells into the body of a patient to replace damaged cells or achieve a stronger immunomodulatory capacity to cure diseases, mainly including stem cell therapy and immune cell therapy. Cell therapy can reduce inflammation, relieve symptoms and promote tissue repair and regeneration of exocrine glands such as the salivary glands. It has broad application prospects and may become a new treatment strategy for patients with SS. However, there are various challenges in cell preparation, culture, storage and transportation. This article reviews the research status and prospects of cell therapies for SS.
引用
收藏
页数:10
相关论文
共 87 条
[1]   Exploiting the role of T cells in the pathogenesis of Sjogren's syndrome for therapeutic treatment [J].
An, Qi ;
Zhao, Jingwen ;
Zhu, Xueqing ;
Yang, Baoqi ;
Wu, Zewen ;
Su, Yazhen ;
Zhang, Liyun ;
Xu, Ke ;
Ma, Dan .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[2]   CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications [J].
Arjomandnejad, Motahareh ;
Kopec, Acadia L. ;
Keeler, Allison M. .
BIOMEDICINES, 2022, 10 (02)
[3]   Haematopoietic stem cell transplants: principles and indications [J].
Balassa, Katalin ;
Danby, Robert ;
Rocha, Vanderson .
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2019, 80 (01) :33-39
[4]   Recent Advances in Extracellular Vesicle-Based Therapies Using Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells [J].
Bertolino, Giuliana Minani ;
Maumus, Marie ;
Jorgensen, Christian ;
Noel, Daniele .
BIOMEDICINES, 2022, 10 (09)
[5]   Introduction to Stem Cell Therapy [J].
Biehl, Jesse K. ;
Russell, Brenda .
JOURNAL OF CARDIOVASCULAR NURSING, 2009, 24 (02) :98-103
[6]   Mesenchymal Stem Cells in Primary Sjogren's Syndrome: Prospective and Challenges [J].
Chen, Weiqian ;
Yu, Ye ;
Ma, Jilin ;
Olsen, Nancy ;
Lin, Jin .
STEM CELLS INTERNATIONAL, 2018, 2018
[7]  
Choi HN., 2013, Journal of Rheumatic Diseases, V20, P118
[8]   Umbilical cord mesenchymal stem cells alleviate Sj?gren?s syndrome and related pulmonary inflammation through regulating V?4+IL-17+T cells [J].
Cong, Yan ;
Tang, Xiaojun ;
Wang, Dandan ;
Zhang, Zhuoya ;
Huang, Saisai ;
Zhang, Xin ;
Yao, Genhong ;
Sun, Lingyun .
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (10)
[9]  
Dan M., 2020, Chinese Journal of Rheumatology, V24, P634, DOI DOI 10.3760/CMA.J.C141217-20190430-00153
[10]   Long-term abatacept treatment for 48 weeks in patients with primary Sjogren's syndrome: The open-label extension phase of the ASAP-III trial [J].
de Wolff, Liseth ;
van Nimwegen, Jolien F. ;
Mossel, Esther ;
van Zuiden, Greetje S. ;
Stel, Alja J. ;
Majoor, Kalle, I ;
Olie, Lisette ;
Los, Leonoor, I ;
Vissink, Arjan ;
Spijkervet, Fred K. L. ;
Verstappen, Gwenny M. P. J. ;
Kroese, Frans G. M. ;
Arends, Suzanne ;
Bootsma, Hendrika .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 53